Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N C Cross

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Blood|September 15, 1996
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemiaA Hochhaus, A Reiter, H Skladny, et al.
Blood|March 10, 2001
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemiaE Olavarria, E Kanfer, R Szydlo, et al.
Bone Marrow Transplantation|June 19, 1998
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donorsF van Rhee, D Savage, J Blackwell, et al.
Bone Marrow Transplantation|January 1, 1993
Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletionJ O Cullis, R M Szydlo, N C Cross, et al.
Blood|December 23, 1999
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemiaF Dazzi, R M Szydlo, C Craddock, et al.
Blood|February 15, 1996
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reactionA Hochhaus, F Lin, A Reiter, et al.
Blood|August 26, 1998
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndromeA Reiter, J Sohal, S Kulkarni, et al.
British Journal of Haematology|December 12, 2001
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapseT I Mughal, A Yong, R M Szydlo, et al.
Science (New York, N.Y.)|September 25, 2001
Roots of clinical resistance to STI-571 cancer therapyA Hochhaus, S Kreil, A Corbin, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Blood|September 15, 1996
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemiaA Hochhaus, A Reiter, H Skladny, et al.
Blood|March 10, 2001
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemiaE Olavarria, E Kanfer, R Szydlo, et al.
Bone Marrow Transplantation|June 19, 1998
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donorsF van Rhee, D Savage, J Blackwell, et al.
Bone Marrow Transplantation|January 1, 1993
Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletionJ O Cullis, R M Szydlo, N C Cross, et al.
Blood|December 23, 1999
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemiaF Dazzi, R M Szydlo, C Craddock, et al.
Blood|February 15, 1996
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reactionA Hochhaus, F Lin, A Reiter, et al.
Blood|August 26, 1998
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndromeA Reiter, J Sohal, S Kulkarni, et al.
British Journal of Haematology|December 12, 2001
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapseT I Mughal, A Yong, R M Szydlo, et al.
Science (New York, N.Y.)|September 25, 2001
Roots of clinical resistance to STI-571 cancer therapyA Hochhaus, S Kreil, A Corbin, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Pageof 12